Annals of Surgical Oncology

, Volume 15, Issue 9, pp 2628–2629 | Cite as

Benefits, Limitations, and Harm of Local Excision for Rectal Cancer

  • D. Ziogas
  • P. Tsekeris
  • E. Fatourou
Radiation Oncology


Rectal Cancer Total Mesorectal Excision Lynch Syndrome Local Excision Cancer Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Enker WE, Thaler HT, Cranor ML, et al. Total mesorectal excision in the operative treatment of carcinoma of the rectum. J Am Coll Surg 1995; 181:335–46.PubMedGoogle Scholar
  2. 2.
    Roukos DH, Kappas AM. Perspectives in the treatment of gastric cancer. Nat Clin Pract Oncol 2005; 2:98–107.PubMedCrossRefGoogle Scholar
  3. 3.
    Roukos DH. Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol 2002; 9:220–1.PubMedGoogle Scholar
  4. 4.
    Clarke M, Collins R, Darby S, et al. Early Breast Cancer Trialists Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005; 366:2087–106.PubMedGoogle Scholar
  5. 5.
    Roukos DH, Murray S, Briasoulis E. Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther 2007; 6:308–12.PubMedGoogle Scholar
  6. 6.
    Roukos DH. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2008; 358:197.PubMedCrossRefGoogle Scholar
  7. 7.
    Roukos DH. Innovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies. Expert Rev Mol Diagn 2008; 8:29–39.PubMedCrossRefGoogle Scholar
  8. 8.
    Liakakos T, Roukos DH. More controversy than ever—Challenges and promises towards personalized treatment of gastric cancer. Ann Surg Oncol 2008 Jan 23 [Epub ahead of print] (DOI:  10.1245/s10434-007-9798-5)
  9. 9.
    Roukos DH, Briasoulis E. Individualized preventive and therapeutic management of hereditary breast ovarian cancer. Nat Clin Pract Oncol 2007; 4:578–90.PubMedCrossRefGoogle Scholar
  10. 10.
    Baik SH, Lee WJ, Rha KH, et al. Robotic total mesorectal excision for rectal cancer using four robotic arms. Surg Endosc 2007 Nov 20 [Epub ahead of print]Google Scholar
  11. 11.
    Borschitz T, Wachtlin D, Möhler M, et al. Neoadjuvant chemoradiation and local excision for T2-3 rectal cancer. Ann Surg Oncol 2008; 15:712–20.PubMedCrossRefGoogle Scholar
  12. 12.
    Roukos DH, Fatouros M, Tsianos E, et al. Does a new model improve decisions about mismatch-repair genetic testing and Lynch syndrome identification? Nat Clin Pract Oncol 2006; 3:656–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003; 348:919–32.PubMedCrossRefGoogle Scholar
  14. 14.
    Roukos DH, Kappas AM, Tsianos E. Role of surgery in the prophylaxis of hereditary cancer syndromes. Ann Surg Oncol 2002; 9:607–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Roukos DH, Agnanti NJ, Paraskevaidis E, et al. Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol 2002; 9:941–3.PubMedGoogle Scholar
  16. 16.
    Norton JA, Ham CM, Van Dam J, et al. CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg 2007; 245:873–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Roukos DH. Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 2007; 357:1555–6; author reply 1556.PubMedCrossRefGoogle Scholar
  18. 18.
    Fatouros M, Baltoyiannis G, Roukos DH. The Predominant Role of Surgery in the Prevention and New Trends in the Surgical Treatment of Women with BRCA1/2 Mutations. Ann Surg Oncol 2008; 15:21–33.PubMedCrossRefGoogle Scholar
  19. 19.
    Agnantis NJ, Paraskevaidis E, Roukos D. Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance. Ann Surg Oncol 2004; 11:1030–4.PubMedCrossRefGoogle Scholar
  20. 20.
    Roukos DH, Kappas AM, Agnantis NJ. Perspectives and risks of breast-conservation therapy for breast cancer. Ann Surg Oncol 2003; 10:718–21.PubMedCrossRefGoogle Scholar
  21. 21.
    Fatouros M, Roukos DH, Arampatzis I, et al. Factors increasing local recurrence in breast-conserving surgery. Expert Rev Anticancer Ther 2005; 5:737–45.PubMedCrossRefGoogle Scholar
  22. 22.
    Roukos DH, Hottenrott C, Encke A, et al. Primary gastric lymphomas: a clinicopathologic study with literature review. Surg Oncol 1994; 3:115–25.PubMedCrossRefGoogle Scholar
  23. 23.
    Roukos DH. Early-stage gastric cancer: a highly treatable disease. Ann Surg Oncol 2004; 11:127–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Briasoulis E, Fatouros M, Roukos DH. Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol 2007; 14:2691–5.PubMedCrossRefGoogle Scholar
  25. 25.
    Roukos DH, Lorenz M, Karakostas K, et al. Pathological serosa and node-based classification accurately predicts gastric cancer recurrence risk and outcome, and determines potential and limitation of a Japanese-style extensive surgery for Western patients: a prospective with quality control 10-year follow-up study. Br J Cancer 2001; 84:1602–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Kappas AM, Fatouros M, Roukos DH. Is it time to change surgical strategy for gastric cancer in the United States? Ann Surg Oncol 2004; 11:727–30.PubMedCrossRefGoogle Scholar
  27. 27.
    Roukos DH, Kappas AM. Targeting the optimal extent of lymph node dissection for gastric cancer. J Surg Oncol 2002; 81:59–62.PubMedCrossRefGoogle Scholar
  28. 28.
    Roukos DH. Extended lymphadenectomy in gastric cancer: when, for whom and why. Ann R Coll Surg Engl1998; 80:16–24.PubMedGoogle Scholar
  29. 29.
    Roukos DH. Extended (D2) lymph node dissection for gastric cancer: do patients benefit? Ann Surg Oncol 2000; 7:253–5.PubMedCrossRefGoogle Scholar
  30. 30.
    Briasoulis E, Liakakos T, Dova L, et al. Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther 2006; 6:931–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Roukos DH. Current advances and changes in treatment strategy may improve survival and quality of life in patients with potentially curable gastric cancer. Ann Surg Oncol 1999; 6:46–56.PubMedCrossRefGoogle Scholar
  32. 32.
    Roukos DH, Lorenz M, Encke A. Evidence of survival benefit of extended (D2) lymphadenectomy in western patients with gastric cancer based on a new concept: a prospective long-term follow-up study. Surgery 1998; 123:573–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Roukos DH. Current status and future perspectives in gastric cancer management. Cancer Treat Rev 2000; 26:243–55.PubMedCrossRefGoogle Scholar
  34. 34.
    Roukos DH. Linking contralateral breast cancer with genetics. Radiother Oncol 2008; 86:139–41.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2008

Authors and Affiliations

  1. 1.Ioannina UniversityIoanninaGreece
  2. 2.Hippocration General HospitalAthensGreece

Personalised recommendations